{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:24:55Z","timestamp":1792085095885,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.neuropharm.2012.07.031","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T20:47:38Z","timestamp":1343854058000},"page":"1258-1267","source":"Crossref","is-referenced-by-count":26,"title":["7-Nitroindazole down-regulates dopamine\/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"63","author":[{"given":"J.E.","family":"Yuste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Echeverry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ros-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fernandez-Villalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2012.07.031_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.physbeh.2004.04.005","article-title":"Evaluation of functional asymmetry in rats with dose-dependent lesions of dopaminergic nigrostriatal system using elevated body swing test","volume":"82","author":"Baluchnejadmojarad","year":"2004","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/glia.20015","article-title":"Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure","volume":"46","author":"Barcia","year":"2004","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.neuropharm.2012.07.031_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.expneurol.2004.03.005","article-title":"Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease","volume":"187","author":"Blandini","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1460-9568.2006.05285.x","article-title":"Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model","volume":"25","author":"Blandini","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib6","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1523\/JNEUROSCI.15-07-05372.1995","article-title":"Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism","volume":"15","author":"Borlongan","year":"1995","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1073\/pnas.87.2.682","article-title":"Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme","volume":"87","author":"Bredt","year":"1990","journal-title":"Proc. Nat. Acad. Sci."},{"issue":"22","key":"10.1016\/j.neuropharm.2012.07.031_bib8","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1523\/JNEUROSCI.20-22-08443.2000","article-title":"Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity","volume":"20","author":"Calabresi","year":"2000","journal-title":"J.\u00a0Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2012.07.031_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2007.03.001","article-title":"Dopamine-mediated regulation of corticostriatal synaptic plasticity","volume":"30","author":"Calabresi","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0006-8993(76)90843-X","article-title":"A\u00a0comparison of circling models for the detection of antiparkinson activity","volume":"41","author":"Costall","year":"1975","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00421307","article-title":"The relationship between striatal and mesolimbic dopamine dysfunction and the nature of circling responses following 6-OHDA and electrolytic lesions of the ascending dopamine systems of rats brain","volume":"118","author":"Costall","year":"1976","journal-title":"Brain Res."},{"issue":"17","key":"10.1016\/j.neuropharm.2012.07.031_bib65","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.88.17.7797","article-title":"Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues","volume":"88","author":"Dawson","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"9","key":"10.1016\/j.neuropharm.2012.07.031_bib12","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1523\/JNEUROSCI.14-09-05147.1994","article-title":"Gases as biological messengers: nitric oxide and carbon monoxide in the brain","volume":"14","author":"Dawson","year":"1994","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.expneurol.2005.01.007","article-title":"Effect of intrastriatal 6-OHDA lesion on dopaminergic innervation of the rat cortex and globus pallidus","volume":"193","author":"Debeir","year":"2005","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2012.07.031_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tox.2004.11.023","article-title":"Peroxynitrite and drug-dependent toxicity","volume":"208","author":"Denicola","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.2008.03678.x","article-title":"Involvement of nitric oxide in nigrostriatal dopaminergic system degeneration: a neurochemical study","volume":"1155","author":"Di Matteo","year":"2009","journal-title":"Ann. NY Acad. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1046\/j.1471-4159.1997.69041771.x","article-title":"Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity","volume":"69","author":"Di Monte","year":"1997","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib17","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1021\/jm040889k","article-title":"Preparation and pharmacological characterization of trans-2-amino5(6)-fluoro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as D2-like dopamine receptor agonists","volume":"48","author":"Di Stefano","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuroscience.2003.12.046","article-title":"Acute and delayed restraint stress-induced changes in nitric oxide producing neurons in limbic regions","volume":"125","author":"Echeverry","year":"2004","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2012.07.031_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0006-8993(99)01166-X","article-title":"Increased nitrotyrosine immunoreactivity in Substantia Nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase","volume":"823","author":"Ferrante","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.brainres.2008.01.088","article-title":"A\u00a0nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway","volume":"1203","author":"Gomes","year":"2008","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0306-4522(99)00415-7","article-title":"Neurocircuitries of the basal ganglia studied in organotypic cultures: focus on tyrosine hydroxylase, nitric oxide synthase and neuropeptide immunocytochemistry","volume":"94","author":"Gomez-Urquijo","year":"1999","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.neuropharm.2012.07.031_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0896-6273(00)80798-9","article-title":"Beyond the dopamine receptor: the DARPP-32\/protein phosphatase-1 cascade","volume":"23","author":"Greengard","year":"1999","journal-title":"Neuron"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2012.07.031_bib23","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1023\/A:1021877512519","article-title":"Treatment with 7-nitroindazole enhances kainic acid induced cholinergic neurotoxicity in the rat striatum: a neuroprotective role for neuronal nitric oxide","volume":"22","author":"Guevara","year":"2002","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib24","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/nm0996-1017","article-title":"Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons","volume":"2","author":"Hantraye","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib25","doi-asserted-by":"crossref","first-page":"14486","DOI":"10.1016\/S0021-9258(17)42625-1","article-title":"DARPP-32, a dopamine- and adenosine 3\u2032:5\u2032-monophosphate-regulated neuronal phosphoprotein. I. Amino acid sequence around the phosphorylated threonine","volume":"259","author":"Hemmings","year":"1984","journal-title":"J.\u00a0Biol. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2012.07.031_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-8993(84)90297-X","article-title":"Evidence that striatal efferents relate to different dopamine receptors","volume":"323","author":"Herrera-Marschitz","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00213-009-1687-0","article-title":"Impact of dopamine-glutamate interactions on striatal neuronal nitric oxide synthase activity","volume":"207","author":"Hoque","year":"2010","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib28","first-page":"19","article-title":"Biochemical pathophysiology of Parkinson's disease","volume":"45","author":"Hornykiewicz","year":"1987","journal-title":"Adv. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2012.07.031_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.HYP.16.5.477","article-title":"Nitric oxide. A novel signal transduction mechanism for transcellular communication","volume":"16","author":"Ignarro","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib30","first-page":"209","article-title":"Behavioral implications of dopaminergic neurons in the mesolimbic system","volume":"16","author":"Iversen","year":"1977","journal-title":"Adv. Biochem. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","article-title":"Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat","volume":"152","author":"Kirik","year":"1998","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2012.07.031_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0006-8993(84)91218-6","article-title":"Neuroleptic-like disruption of the avoidance response requires destruction of both the mesolimbic and nigrostriatal dopamine systems","volume":"303","author":"Koob","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nature00817","article-title":"Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine","volume":"418","author":"Lindskog","year":"2002","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.neuropharm.2012.07.031_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0092-8674(94)90268-2","article-title":"Nitric oxide synthase: aspects concerning structure and catalysis","volume":"78","author":"Marletta","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib35","first-page":"109","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2012.07.031_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0166-2236(93)90109-Y","article-title":"Synthesis of nitric oxide in CNS glial cells","volume":"16","author":"Murphy","year":"1993","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neuropharm.2004.05.010","article-title":"The role of DARPP-32 in the actions of drugs of abuse","volume":"47","author":"Nairn","year":"2004","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1073\/pnas.0409138102","article-title":"Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades","volume":"102","author":"Nishi","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/(SICI)1098-2396(19991201)34:3<228::AID-SYN7>3.0.CO;2-Z","article-title":"Subthalamic responses to amphetamine and apomorphine in the behaving rat with a unilateral 6-OHDA lesion in the Substantia Nigra","volume":"34","author":"Old","year":"1999","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.neuropharm.2012.07.031_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-8993(98)00724-0","article-title":"DARPP-32, a dopamine- and adenosine 3\u2032:5\u2032-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization","volume":"4","author":"Ouimet","year":"1984","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib41","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0006-8993(98)00724-0","article-title":"Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen","volume":"808","author":"Ouimet","year":"1998","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.neuropharm.2012.07.031_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.neuroscience.2009.01.034","article-title":"Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"159","author":"Padovan-Neto","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib43","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1111\/j.1471-4159.2009.06416.x","article-title":"Regulation of striatal nitric oxide synthesis by local dopamine and glutamate interactions","volume":"111","author":"Park","year":"2009","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib44","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1998"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/187152711798072329","article-title":"Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders","volume":"10","author":"Pierucci","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0306-4522(95)00066-R","article-title":"Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine","volume":"67","author":"Przedborski","year":"1995","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2012.07.031_bib47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","article-title":"Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism","volume":"25","author":"Sagi","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.brainres.2007.12.054","article-title":"Modulation of dopamine uptake by nitric oxide in cultured mesencephalic neurons","volume":"1198","author":"Salum","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib49","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/sj.npp.1300826","article-title":"Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1\/5) receptor-dependent mechanism","volume":"31","author":"Sammut","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2012.07.031_bib52","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.neuroscience.2006.10.004","article-title":"Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease","volume":"144","author":"Smith","year":"2007","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.neuropharm.2012.07.031_bib53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0006-2952(95)02099-3","article-title":"Selective pharmacological inhibition of distinct nitric oxide synthase isoforms","volume":"51","author":"Southan","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.44.101802.121415","article-title":"DARPP-32: an integrator of neurotransmission","volume":"44","author":"Svenningsson","year":"2004","journal-title":"Ann. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib55","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1073\/pnas.90.8.3462","article-title":"Nitric oxide\/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine- and cAMP-regulated phosphoprotein, in the Substantia Nigra","volume":"90","author":"Tsou","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2012.07.031_bib56","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"Ungerstedt","year":"1970","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib58","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0306-4522(92)90184-4","article-title":"Histochemical mapping of nitric oxide synthase in the rat brain","volume":"46","author":"Vincent","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2012.07.031_bib59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/syn.20075","article-title":"L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism","volume":"54","author":"Volz","year":"2004","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.neuropharm.2012.07.031_bib60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00441-004-0921-7","article-title":"Synucleins and their relationship to Parkinson's disease","volume":"318","author":"Von Bohlen Und Halbach","year":"2004","journal-title":"Cell. Tissue Res."},{"issue":"8","key":"10.1016\/j.neuropharm.2012.07.031_bib61","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1523\/JNEUROSCI.4470-03.2004","article-title":"The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in\u00a0vivo","volume":"24","author":"West","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib62","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fnsys.2011.00055","article-title":"Nitric oxide-soluble guanylyl cyclase-cyclic GMP signaling in the striatum: new targets for the treatment of Parkinson's disease?","volume":"5","author":"West","year":"2011","journal-title":"Front. Syst. Neurosci."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0003-2697(88)90383-1","article-title":"Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for colour formation","volume":"175","author":"Wiechelman","year":"1988","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2012.07.031_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jneumeth.2004.10.004","article-title":"Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease","volume":"144","author":"Yuan","year":"2005","journal-title":"J.\u00a0Neurosci. Methods"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081200367X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081200367X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T04:52:48Z","timestamp":1643086368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081200367X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S002839081200367X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2012.07.031","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}